TY - JOUR
T1 - Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review
AU - Arcangeli, Stefano
AU - Scorsetti, Marta
AU - Alongi, Filippo
PY - 2012/10
Y1 - 2012/10
N2 - Stereotactic body radiation therapy (SBRT) is a novel treatment modality in radiation oncology that delivers a very high dose of radiation to the tumor target with high precision using single or a small number of fractions. SBRT is the result of technological advances in patient/tumor immobilization, image guidance, and treatment planning and delivery. This modality is safe and effective in both early stage primary cancer and oligometastases. Compared to the use of stereotactic radiosurgery for other tumor sites, SBRT is slow to be adopted in the management of genitourinary malignancies. Emerging data show the safety and efficacy of this treatment modality in prostate cancer. Preclinical data, clinical experience, and challenges are reviewed and discussed.
AB - Stereotactic body radiation therapy (SBRT) is a novel treatment modality in radiation oncology that delivers a very high dose of radiation to the tumor target with high precision using single or a small number of fractions. SBRT is the result of technological advances in patient/tumor immobilization, image guidance, and treatment planning and delivery. This modality is safe and effective in both early stage primary cancer and oligometastases. Compared to the use of stereotactic radiosurgery for other tumor sites, SBRT is slow to be adopted in the management of genitourinary malignancies. Emerging data show the safety and efficacy of this treatment modality in prostate cancer. Preclinical data, clinical experience, and challenges are reviewed and discussed.
KW - Hypofractionation
KW - Prostate cancer
KW - Stereotactic body radiation therapy (SBRT)
UR - http://www.scopus.com/inward/record.url?scp=84866483298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866483298&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2011.11.009
DO - 10.1016/j.critrevonc.2011.11.009
M3 - Article
C2 - 22257653
AN - SCOPUS:84866483298
VL - 84
SP - 101
EP - 108
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
IS - 1
ER -